TIL logo

INSTIL BIO INC

TILNASDAQ
🏆 #4380 by market capEarnings Nov 11US Equity
$6.88▲ $1.06 (+18.21%)
Latest quote
🔔
Track TIL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 18.2%
7d▲ 19.9%
14d▲ 13.9%
30d▼ 3.8%
ytd▼ 33.8%
1y▼ 61.1%
🏦Market Cap
$47M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$6.16 – $6.88
52-Week Range
$5.57 – $20.11
Volume (shares)
1,025
Avg Volume (shares)
—
Shares Outstanding
6.8M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-4.47
Dividend Yield
—
Dilution (1yr)
+3.9%
TIL logo

INSTIL BIO INC

TIL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$53M▼ −28.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$37M▼ −44.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.8M▲ +3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$79M▼ −$459K YoY
StockOtter · stockotter.space

About INSTIL BIO INC

Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
8 analysts
Strong Buy0
Buy0
Hold3
Sell4
Strong Sell1
Ratings as of Oct 2026

Latest News & Updates

News unavailable.